Why is this study being conducted?
This research project is testing a new potential treatment for chronic kidney disease. The new treatment is called Zibotentan in combination with Dapagliflozin (Forxiga).
We are doing this study to determine whether Zibotentan in combination with Dapagliflozin is safer and more effective than dapagliflozin by itself for treatment of chronic kidney disease (CKD). This study will also help better understand the CKD and associated health problems.
Who is eligible to participate in this study?
You may be able to take part in the CKD Trial if you:
- Are above 18 years of age
- Have a diagnosis of chronic kidney disease
- Are capable of giving signed informed consent
Additional eligibility criteria may apply and will be discussed directly with the Clinical Trial Coordinator.
What happens during the study?
- Trial duration will be up to 33 months (approx 3 years) and participants will have about 14 trial visits.
- Trial site visits will occur at the Griffith University Clinical Trial Unit on the Gold Coast.
- You will take 1 tablet of either the study drug or comparator by mouth once daily.
Participation in this study is completely voluntary, and participants can decide to withdraw at any time.
Eligible participants will be reimbursed for their travel associated with each study visit.
For further information please contact Tracey Brumby (Clinical Trial Coordinator) on 0481 484 286 or email: [email protected].
Ethics approval number for the CKD Trial: Bellberry Limited 2023-09-1089-AB, GU HREC 2023/825
